11/10/2009

Roche Holding's RG1678 improved symptoms as well as personal and social functioning of schizophrenics in a Phase II trial, the company reported. The compound, which is co-developed with Chugai Pharmaceutical, was also well-tolerated at all doses.

Full Story:
Reuters

Related Summaries